文献速递疼痛医学

癌症疼痛鞘内阿片治疗中血清阿片水平与临床结局的前瞻性关联

Prospective Association of Serum Opioid Levels and Clinical Outcomes in Patients With Cancer Pain Treated With Intrathecal Opioid Therapy.
PubMed 文献 · Anesth Analg · 2020-01-01

ITT后多数患者血清阿片浓度显著下降甚至检测不到,疼痛与症状评分改善且不依赖血清水平,便秘明显减轻,并发症率很低。

要点

  • ITT后4周53%、8周59%患者血清阿片浓度检测不到(<2 ng/mL)。
  • ITT吗啡剂量>4.2 mg/d均伴可检测血清水平,<4.2 mg/d时80%检测不到。
  • 疼痛与症状改善独立于血清阿片水平,便秘从58.7%降至4周19.2%。

核心结论

  • 癌症疼痛ITT与血清阿片浓度显著降低相关,多数患者血清水平检测不到。
  • 血清阿片浓度降低可能有助于恢复肠道功能、改善疲劳及维护抗肿瘤免疫,值得进一步研究。

研究设计与样本

  • 在植入时及术后4周、8周采集每日口服吗啡等效剂量(OME)、血清阿片水平、简明疼痛量表(BPI)、MD Anderson症状量表(MDASI)及便秘问卷。

主要发现

  • 基线平均每日OME为375 mg(中位240;四分位距150-405;范围0-3160)。
  • 基线平均血清吗啡浓度为53.7 ng/mL(n=17),平均羟考酮浓度为73.7 ng/mL(n=20)。
  • 4周时87.5%患者停用非ITT阿片,53%血清阿片浓度检测不到(<2 ng/mL);8周时92%仍停用非ITT阿片,59%检测不到。
  • ITT吗啡剂量>4.2 mg/d均伴可检测血清水平,<4.2 mg/d时80%受试者检测不到;ITT氢吗啡酮剂量>6.8 mg/d可检测到血清水平。
  • 线性混合模型分析显示4周和8周平均「最差疼痛」「平均疼痛」及MDASI严重程度与干扰评分显著下降,且独立于血清阿片水平。

临床怎么用

  • ITT可显著降低癌症疼痛患者的全身阿片暴露,多数患者血清阿片检测不到。
  • ITT吗啡剂量>4.2 mg/d或氢吗啡酮>6.8 mg/d时血清阿片可检测,可据此评估全身暴露。
  • 疼痛与症状改善不依赖血清阿片水平,提示ITT的中枢镇痛作用独立于全身浓度。

局限性

  • 8周便秘改善的P值为.23,未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Opioids remain the mainstay of cancer pain management but are associated with systemic toxicity. In refractory cancer pain, intrathecal therapy (ITT) is associated with improved pain control, reduced systemic side effects, and improved survival. It has been assumed that ITT decreases systemic serum opioid levels and their associated toxicity, but there are limited data to support this assumption. This study hypothesizes that serum opioid levels decrease with ITT. Secondary objectives include comparative measures of pain, bowel function, and other cancer-related symptoms. METHODS: Fifty-one cancer patients undergoing ITT for cancer pain were recruited in a prospective observational study. Daily oral morphine equivalency (OME) dose, serum opioid levels, Brief Pain Inventory (BPI), MD Anderson Symptom Inventory (MDASI), and a constipation questionnaire were obtained at the time of implant, and 4 and 8 weeks postoperatively. RESULTS: Average baseline daily OME was 375 mg (median, 240; interquartile range, 150-405; range, 0-3160), mean serum morphine concentration was 53.7 ng/mL (n = 17), and mean oxycodone concentration was 73.7 ng/mL (n = 20). At 4 weeks, 87.5% of patients had discontinued non-IT opioids, and 53% had undetectable (<2 ng/mL) serum opioid concentrations. At 8 weeks, 92% remained off all non-IT opioids and 59% had undetectable serum opioid levels. IT morphine doses >4.2 mg/d were invariably associated with detectable serum levels; with doses <4.2 mg, morphine was undetectable in 80% of subjects. IT hydromorphone doses >6.8 mg/d were detectable in the serum. Using linear mixed model analyses, there were statistically significant decreases in the mean "worst pain," "average pain," and MD Anderson symptom severity and interference scores at 4 and 8 weeks. This change was independent of serum opioid levels; when analyzed separately, there was no difference in the pain scores of subjects with detectable serum opioid levels compared to those with undetectable levels at 4 and 8 weeks. Constipation ranked as "quite a bit" or "very much" decreased from 58.7% to 19.2% of subjects at week 4 (P < .001) and to 37.5% at 8 weeks (P = .23). A very low complication rate was observed. CONCLUSIONS: ITT for cancer pain was associated with a marked reduction in serum opioid concentrations, with the majority of patients having undetectable serum levels. Reducing serum opioid concentrations in cancer patients may have implications with respect to restoring bowel function, improving fatigue, and promoting the integrity of antitumor immune function and warrants further study.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Brogan SE, Sindt JE, Jackman CM, et al. Prospective Association of Serum Opioid Levels and Clinical Outcomes in Patients With Cancer Pain Treated With Intrathecal Opioid Therapy. Anesth Analg. 2020. PMID: 31206429. doi:10.1213/ANE.0000000000004276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。